ImmunityBio surges as ANKTIVA revenue jumps 700% in breakthrough 2025
Share
ImmunityBio (NASDAQ:IBRX), the California-based immunotherapy leader, reported explosive 2025 financial results on Monday, signaling its successful transition into a high-growth commercial powerhouse.
